CClinicalTrials.gg
Status unknownNCT03725748Updated Oct 31, 2018

Normal Saline Versus Betadine Use to Reduce the Incidence of Wound Infection in Cesarean Section

A Phase 2 interventional study of irrigation in Incidence of cs Scar Infection, sponsored by Kasr El Aini Hospital. Status unknown at 1 site in Egypt. Open to female participants aged 19 Years to 37 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-31.

Sponsored by Kasr El Aini Hospital · Phase 2, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
19 Years to 37 Years
Sex
Female
01

Study summary

This is a prospective randomized controlled study to the difference between using normal saline or betadine irrigation of wound prior to skin closure in reducing the incidence of wound infection after Cesarean section.

Read the detailed description

This study will be conducted at the Department of Obstetrics \& Gynecology, Kasr El-Ainy Teaching Hospital, Faculty of Medicine, Cairo University, from February to July 2018.

We include in our study 3oo pregnant women who will undergo Cesarean section. All participants will be divided into 3 groups with a 1:1:1 ratio with 100 patients in each group. Each participant will provide an informed written consent.

Consenting patients will be pre-operatively randomised using numerically ordered cards in sealed envelopes to either the group 1 (wound irrigation with 100 ml of normal saline before skin closure) or the group 2 (wound irrigation with 50 ml of 10% aqueous povidone iodine solution ̋ Betadinȅ ) or the control group (no wound irrigation with normal saline nor betadine).Subjects candidate for the study will be 37 weeks' gestation and require a cesarean section (elective or emergency). Patients with allergy to iodine, history of immunosuppressive drug use, gestationaldiabetes mellitus or preeclampsia, anemic patients, ruptured of membranes and feverish patients will be excluded from the study.

The primary outcome will be the incidence of wound infection. Wound infection is diagnosed when the wound drained purulent material or serosanguineous fluid in association with induration, warmth and tenderness. Suspected wound infections are opened for confirmation and wound cultures will be taken. Haematoma, seroma, or wound breakdown in the absence of the previouslydiscussed signs is not considered a wound infection.Wounds are examined twice daily during hospitalization for evidence of infection. After discharge, the women are instructed on the signs and symptoms of wound infection, and asked to contact one of the co-authors immediately if any of the listed symptoms appeared. All participants are examined at 2 and 6 weeks after surgery.

02

Conditions studied

  • Incidence of cs Scar Infection

Keywords

  • saline, betadine, cesarean scar infection
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's planned enrollment of 300 is above the median of 120 across 4,200 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Kasr El Aini Hospital is the lead sponsor of 273 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Subjects candidate for the study will be 37 weeks' gestation
  • require a cesarean section (elective or emergency).

Exclusion criteria

Exclusion Criteria:

  • Patients with allergy to iodine
  • history of immunosuppressive drug use,
  • gestationaldiabetes mellitus
  • preeclampsia
  • anemic patients
  • ruptured of membranes
  • feverish patients
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • No intervention
    no irrigation group

    nothing used for irrigation of cs scar

  • Placebo comparator
    saline irrigation group

    saline used for irrigation the cs scar before closure

    Other: irrigation

  • Experimental
    betadine irrigation group

    betadine used for irrigation of cs scar

    Other: irrigation

Interventions

  • Otherirrigation

    irrigation the edges of the cs scar before closure

06

What researchers measure

Primary outcomes

  1. incidence of cs scar infection

    incidence of cs scar infection

    Time frame: 2 to 6 weeks

Secondary outcomes

  1. incidence of hematoma, seroma

    incidence of hematoma, seroma, wound breakdown

    Time frame: 2 to 6 weeks

07

Study locations

1 site
  • Kasr El Ainy
    Cairo, 02, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03725748
Lead sponsor
Kasr El Aini Hospital
Responsible party
hadeer meshal (assistant prfessor, Kasr El Aini Hospital) — Principal investigator
First posted
Oct 31, 2018
Start date
Nov 1, 2018 (estimated)
Primary completion
May 2019 (estimated)
Completion
Jun 2019 (estimated)
Last update
Oct 31, 2018

Study contacts

hany saad, assistant prof
Contact
dr_hanysaad@yahoo.co.uk
01001817211
ashraf saad, lecturer
Contact
ashraf@yahoo.co.uk
01001817221
fady salah, lecturer
study director · Director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion